200MO Anti–IL-8 BMS-986253 + nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with advanced cancer: Update of initial phase I results. (December 2022) - Simonelli, M.; Calvo, E.; Davar, D.; Richards, D.; Gutierrez, M.; Moreno Garcia, V.; Marron, T.; Rottey, S.; Orcurto, A.; Renouf, D.J.; Joerger, M.; Barriga Falcon, S.; et al.